These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25985881)

  • 1. Diagnostic Value of Urinary Steroid Profiling in the Evaluation of Adrenal Tumors.
    Kerkhofs TM; Kerstens MN; Kema IP; Willems TP; Haak HR
    Horm Cancer; 2015 Aug; 6(4):168-75. PubMed ID: 25985881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical Carcinoma.
    Velikanova LI; Shafigullina ZR; Lisitsin AA; Vorokhobina NV; Grigoryan K; Kukhianidze EA; Strelnikova EG; Krivokhizhina NS; Krasnov LM; Fedorov EA; Sablin IV; Moskvin AL; Bessonova EA
    Horm Cancer; 2016 Dec; 7(5-6):327-335. PubMed ID: 27370636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.
    Arlt W; Biehl M; Taylor AE; Hahner S; Libé R; Hughes BA; Schneider P; Smith DJ; Stiekema H; Krone N; Porfiri E; Opocher G; Bertherat J; Mantero F; Allolio B; Terzolo M; Nightingale P; Shackleton CH; Bertagna X; Fassnacht M; Stewart PM
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3775-84. PubMed ID: 21917861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Resolution, Accurate-Mass (HRAM) Mass Spectrometry Urine Steroid Profiling in the Diagnosis of Adrenal Disorders.
    Hines JM; Bancos I; Bancos C; Singh RD; Avula AV; Young WF; Grebe SK; Singh RJ
    Clin Chem; 2017 Dec; 63(12):1824-1835. PubMed ID: 28814383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of urinary steroid profiling for diagnosing and monitoring adrenocortical tumours.
    Tiu SC; Chan AO; Taylor NF; Lee CY; Loung PY; Choi CH; Shek CC
    Hong Kong Med J; 2009 Dec; 15(6):463-70. PubMed ID: 19966352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma.
    Gröndal S; Eriksson B; Hagenäs L; Werner S; Curstedt T
    Acta Endocrinol (Copenh); 1990 May; 122(5):656-63. PubMed ID: 2141212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified urinary steroid profiling by LC-MS as diagnostic tool for malignancy in adrenocortical tumors.
    Vogg N; Müller T; Floren A; Dandekar T; Riester A; Dischinger U; Kurlbaum M; Kroiss M; Fassnacht M
    Clin Chim Acta; 2023 Mar; 543():117301. PubMed ID: 36948238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma.
    Schweitzer S; Kunz M; Kurlbaum M; Vey J; Kendl S; Deutschbein T; Hahner S; Fassnacht M; Dandekar T; Kroiss M
    Eur J Endocrinol; 2019 Feb; 180(2):117-125. PubMed ID: 30481155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 13-Steroid Serum Panel Based on LC-MS/MS: Use in Detection of Adrenocortical Carcinoma.
    Taylor DR; Ghataore L; Couchman L; Vincent RP; Whitelaw B; Lewis D; Diaz-Cano S; Galata G; Schulte KM; Aylwin S; Taylor NF
    Clin Chem; 2017 Dec; 63(12):1836-1846. PubMed ID: 28904054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary steroid profile in adrenocortical tumors.
    Kikuchi E; Yanaihara H; Nakashima J; Homma K; Ohigashi T; Asakura H; Tachibana M; Shibata H; Saruta T; Murai M
    Biomed Pharmacother; 2000 Jun; 54 Suppl 1():194s-197s. PubMed ID: 10915023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary steroid profiling in diagnostic evaluation of an unusual adrenal mass.
    Lenders NF; Greenfield JR
    Endocrinol Diabetes Metab Case Rep; 2019 Nov; 2019():. PubMed ID: 31778357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma.
    Chortis V; Bancos I; Nijman T; Gilligan LC; Taylor AE; Ronchi CL; O'Reilly MW; Schreiner J; Asia M; Riester A; Perotti P; Libé R; Quinkler M; Canu L; Paiva I; Bugalho MJ; Kastelan D; Dennedy MC; Sherlock M; Ambroziak U; Vassiliadi D; Bertherat J; Beuschlein F; Fassnacht M; Deeks JJ; Biehl M; Arlt W
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e307-18. PubMed ID: 31665449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11 Beta-hydroxylase deficiency congenital adrenal hyperplasia: update of prenatal diagnosis.
    Rösler A; Weshler N; Leiberman E; Hochberg Z; Weidenfeld J; Sack J; Chemke J
    J Clin Endocrinol Metab; 1988 Apr; 66(4):830-8. PubMed ID: 3346360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Carcinoma of the adrenal cortex].
    Hamborg B; Frey H; Bøhmer T; Norman N
    Tidsskr Nor Laegeforen; 1990 Mar; 110(8):956-9. PubMed ID: 2321225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
    Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of urinary steroid profile in patients with adrenal tumor as a screening method for carcinoma.
    Minowada S; Kinoshita K; Hara M; Isurugi K; Uchikawa T; Niijima T
    Endocrinol Jpn; 1985 Feb; 32(1):29-37. PubMed ID: 4017973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study.
    Bancos I; Taylor AE; Chortis V; Sitch AJ; Jenkinson C; Davidge-Pitts CJ; Lang K; Tsagarakis S; Macech M; Riester A; Deutschbein T; Pupovac ID; Kienitz T; Prete A; Papathomas TG; Gilligan LC; Bancos C; Reimondo G; Haissaguerre M; Marina L; Grytaas MA; Sajwani A; Langton K; Ivison HE; Shackleton CHL; Erickson D; Asia M; Palimeri S; Kondracka A; Spyroglou A; Ronchi CL; Simunov B; Delivanis DA; Sutcliffe RP; Tsirou I; Bednarczuk T; Reincke M; Burger-Stritt S; Feelders RA; Canu L; Haak HR; Eisenhofer G; Dennedy MC; Ueland GA; Ivovic M; Tabarin A; Terzolo M; Quinkler M; Kastelan D; Fassnacht M; Beuschlein F; Ambroziak U; Vassiliadi DA; O'Reilly MW; Young WF; Biehl M; Deeks JJ; Arlt W;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):773-781. PubMed ID: 32711725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
    Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
    Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling.
    Bancos I; Arlt W
    Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):200-207. PubMed ID: 28234802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenocortical adenomas with regression and myelolipomatous changes: urinary steroid profiling supports a distinctive benign neoplasm.
    Perna V; Taylor NF; Dworakowska D; Schulte KM; Aylwin S; Al-Hashimi F; Diaz-Cano SJ
    Clin Endocrinol (Oxf); 2014 Sep; 81(3):343-9. PubMed ID: 24712713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.